Zacks Investment Research downgraded shares of Trinity Biotech PLC (NASDAQ:TRIB) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning.

According to Zacks, “Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market worldwide. The company provides two haemostasis product lines, Biopool and Amax, comprising test kits and instrumentation used for the detection of blood disorders. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the blood, liver and intestine. The Company is also a provider of raw materials to the life sciences industry. It also engages in the provision of engineering, financial, and management services, as well as in trading business. Trinity Biotech sells its products through its sales force, as well as through a network of distributors and strategic partners. “

Separately, ValuEngine lowered shares of Trinity Biotech PLC from a hold rating to a sell rating in a research report on Friday, June 2nd.

Trinity Biotech PLC (NASDAQ TRIB) opened at 5.56 on Wednesday. The company has a 50 day moving average of $5.44 and a 200 day moving average of $5.63. Trinity Biotech PLC has a 1-year low of $5.11 and a 1-year high of $13.34. The firm’s market capitalization is $121.47 million.

Trinity Biotech PLC (NASDAQ:TRIB) last posted its quarterly earnings data on Thursday, July 20th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.03). Trinity Biotech PLC had a negative net margin of 100.45% and a positive return on equity of 5.54%. The firm had revenue of $25.45 million during the quarter, compared to analysts’ expectations of $24.83 million. Analysts forecast that Trinity Biotech PLC will post $0.27 EPS for the current year.

WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.watchlistnews.com/zacks-investment-research-downgrades-trinity-biotech-plc-trib-to-hold/1584246.html.

A number of large investors have recently bought and sold shares of the stock. Paradice Investment Management LLC grew its position in Trinity Biotech PLC by 0.8% in the 2nd quarter. Paradice Investment Management LLC now owns 1,639,296 shares of the company’s stock valued at $9,836,000 after buying an additional 12,800 shares during the last quarter. Heartland Advisors Inc. lifted its holdings in Trinity Biotech PLC by 1.3% in the second quarter. Heartland Advisors Inc. now owns 1,565,550 shares of the company’s stock valued at $9,393,000 after acquiring an additional 20,000 shares during the period. Janus Henderson Group PLC acquired a new stake in Trinity Biotech PLC in the second quarter valued at $8,486,000. Lapides Asset Management LLC lifted its holdings in Trinity Biotech PLC by 0.4% in the second quarter. Lapides Asset Management LLC now owns 1,289,600 shares of the company’s stock valued at $7,738,000 after acquiring an additional 5,500 shares during the period. Finally, First Wilshire Securities Management Inc. lifted its holdings in Trinity Biotech PLC by 21.7% in the first quarter. First Wilshire Securities Management Inc. now owns 1,075,221 shares of the company’s stock valued at $6,408,000 after acquiring an additional 191,650 shares during the period. Hedge funds and other institutional investors own 62.97% of the company’s stock.

About Trinity Biotech PLC

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.

Get a free copy of the Zacks research report on Trinity Biotech PLC (TRIB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Trinity Biotech PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.